

Edgar Filing: HYDROMER INC - Form 10-Q

HYDROMER INC  
Form 10-Q  
February 22, 2011

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON D.C. 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended December 31, 2010

Commission File Number 0-10683

HYDROMER, INC.  
-----

(Exact name of registrant as specified in its charter)

New Jersey ----- (State of incorporation)	22-2303576 ----- (I.R.S. Employer Identification No.)
35 Industrial Pkwy, Branchburg, New Jersey ----- (Address of principal executive offices)	08876-3424 ----- (Zip Code)
Registrant's telephone number, including area code:	(908) 722-5000 -----

Securities registered pursuant to Section 12 (b) of the Act: None

Securities registered pursuant to Section 12 (g) of the Act:

Common Stock Without Par Value  
(Title of class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  
Yes  No

Class -----	Outstanding at December 31, 2010 -----
Common	4,772,318

-----  
FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, among other things, business strategy and expectations concerning industry conditions, market position, future operations, margins, profitability, liquidity and capital resources. Forward-looking statements generally can be identified by the use of terminology such as "may," "will," "expect," "intend," "estimate," "anticipate" or "believe" or similar expressions or the negatives thereof. These expectations are based on management's assumptions and current beliefs based on currently available information. Although the Company believes that the expectations reflected in such statements are reasonable, it can give no assurance that such expectations will be correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this quarterly report on Form 10-Q and the Company does not have any obligation to update the forward looking statements. The Company's operations are subject to a number of uncertainties, risks and other influences, many of which are outside its control, and any one of which, or a combination of which, could cause its actual results of operations to differ materially from the forward-looking statements.

Edgar Filing: HYDROMER INC - Form 10-Q

HYDROMER, INC.

INDEX TO FORM 10-Q  
December 31, 2010

	Page No.
Part I - Financial Information	
# 1 Consolidated Financial Statements	
Balance Sheets - December 31, 2010 & June 30, 2010	3
Statements of Operations for the three months and six months ended December 31, 2010 and 2009	4
Statements of Cash Flows for the six months ended December 31, 2010 and 2009	5
Notes to Financial Statements	6
# 2 Management's Discussion and Analysis of the Financial Condition and Results of Operations	7
# 3 Controls and Procedures	9

## Edgar Filing: HYDROMER INC - Form 10-Q

### Part II - Other Information

# 1	Legal Proceedings	N/A
# 2	Change in Securities	N/A
# 3	Default of Senior Securities	N/A
# 4	Submission of Motion to Vote of Security Holders	N/A
# 5	Other Information	N/A
# 6	Exhibits	9

### EXHIBIT INDEX

Exhibit No.	Description of Exhibit	
-----	-----	
31.1	SEC Section 302 Certification - CEO certification	10
31.2	SEC Section 302 Certification - CFO certification	11
32.1	Certification of Manfred F. Dyck, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350	12
32.2	Certification of Robert Y. Lee, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350	12

PART I - CONSOLIDATED FINANCIAL STATEMENTS  
ITEM # 1

HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY  
CONSOLIDATED BALANCE SHEETS

Edgar Filing: HYDROMER INC - Form 10-Q

ASSETS	December 31, 2010 UNAUDITED	June 2011 AUDITED
Current Assets:		
Cash and cash equivalents	\$ 613,903	\$ 84
Short-term investments	-	44
Trade receivables less allowance for doubtful accounts of \$31,335 and \$33,276 as of December 31, 2010 and June 30, 2010, respectively	812,999	92
Inventory	318,566	24
Prepaid expenses	150,799	22
Other	1,150	1
<hr/>		
Total Current Assets	1,897,417	2,69
<hr/>		
Property and equipment, net	2,948,957	2,98
Deferred tax asset, non-current	1,191,828	1,01
Intangible assets, net	845,091	83
<hr/>		
Total Assets	\$ 6,883,293	\$ 7,53
<hr/>		
LIABILITIES AND STOCKHOLDERS' EQUITY		
<hr/>		
Current Liabilities:		
Accounts payable	\$ 266,104	\$ 34
Accrued expenses	212,892	25
Current portion of capital lease	16,788	1
Current portion of deferred revenue	78,023	7
Current portion of mortgage payable	50,508	4
Income tax payable	3,891	
<hr/>		
Total Current Liabilities	628,206	73
<hr/>		
Deferred tax liability	283,375	31
Long-term portion of capital lease	25,677	3
Long-term portion of deferred revenue	142,977	16
Long-term portion of mortgage payable	2,742,379	2,76
<hr/>		
Total Liabilities	3,822,614	4,02
<hr/>		
Stockholders' Equity		
Preferred stock - no par value, authorized 1,000,000 shares, no shares issued and outstanding	-	
Common stock - no par value, authorized 15,000,000 shares; 4,783,235 shares issued and 4,772,318 shares outstanding as of December 31, 2010 and June 30, 2010	3,721,815	3,72
Contributed capital	633,150	63
Accumulated deficit	(1,288,146)	(83
Treasury stock, 10,917 common shares at cost	(6,140)	(
<hr/>		
Total Stockholders' Equity	3,060,679	3,51
<hr/>		
Total Liabilities and Stockholders' Equity	\$ 6,883,293	\$ 7,53
<hr/>		

See accompanying notes

HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY  
CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended December 31,		
	2010 UNAUDITED	2009 UNAUDITED	2008 UNAUDITED
<hr/>			
REVENUES			
Sale of products	\$ 560,330	\$ 829,402	\$ 1,211,114
Service revenues	401,068	359,491	77,914
Royalties and Contract Revenues	244,727	227,221	48,914
	<hr/>	<hr/>	<hr/>
TOTAL REVENUES	1,206,125	1,416,114	2,466,942
<hr/>			
EXPENSES			
Cost of Sales	321,983	627,263	74,914
Operating Expenses	1,077,919	1,221,493	2,271,114
Other Expenses	48,683	30,024	9,914
Gain from Sale of Assets	-	(335,629)	-
Benefit from Income Taxes	(44,504)	(49,900)	(20,914)
	<hr/>	<hr/>	<hr/>
TOTAL EXPENSES	1,404,081	1,493,251	2,916,942
<hr/>			
NET LOSS	\$ (197,956)	\$ (77,137)	\$ (450,000)
<hr/>			
Loss Per Common Share	\$ (0.04)	\$ (0.02)	\$ (0.04)
<hr/>			
Weighted Average Number of Common Shares Outstanding	4,772,318	4,772,318	4,772,318

See accompanying notes.

There was no impact to earnings per share from dilutive securities as the resultant would have been anti-dilutive.

HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY  
CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six months Ended December 31,	20
	2010 UNAUDITED	20 UNAUDITED
<hr/>		
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Loss	\$ (452,906)	\$ (349,000)
Adjustments to reconcile net loss to net cash used for operating activities		
Gain on Sale of Product Lines	-	(335,000)
Depreciation and amortization	200,838	220,000
Deferred income taxes	(214,883)	(227,000)
Changes in Assets and Liabilities:		
Trade receivables	107,253	350,000
Inventory	(69,997)	61,000
Prepaid expenses	63,912	54,000
Other assets	14,337	(11,000)
Accounts payable and accrued liabilities	(121,416)	(116,000)
Deferred income	(20,641)	12,000
Income taxes payable	3,891	(73,000)
	<hr/>	<hr/>
Net Cash Used in Operating Activities	(489,612)	(415,000)
<hr/>		
CASH FLOWS FROM INVESTING ACTIVITIES:		
Cash purchases of property and equipment	(66,390)	(126,000)
Cash payments on patents and trademarks	(88,756)	(156,000)
Redemption of matured short-term investments	440,000	260,000
Cash purchases of short-term investments	-	(250,000)
Proceeds Received from the sale of Product Lines	-	400,000
	<hr/>	<hr/>

## Edgar Filing: HYDROMER INC - Form 10-Q

Net Cash Provided by Investing Activities	284,854	127
<hr style="border-top: 1px dashed black;"/>		
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repayment of long-term borrowings	(24,949)	(23)
<hr style="border-top: 1px dashed black;"/>		
Net Cash Used in Financing Activities	(24,949)	(23)
<hr style="border-top: 1px dashed black;"/>		
NET DECREASE IN CASH AND CASH EQUIVALENTS:		
Cash and Cash Equivalents at Beginning of Period	843,610	1,585
<hr style="border-top: 1px dashed black;"/>		
Cash and Cash Equivalents at End of Period	\$ 613,903	\$ 1,274
<hr style="border-top: 1px dashed black;"/>		
Non-Cash Investing and Financing Activities:		
Note Receivable in exchange for Sale of Product Lines		\$ 400

See accompanying notes.

### HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY

#### Notes to Consolidated Financial Statements

In the opinion of management, the accompanying unaudited financial statements include all adjustments (consisting of only normal adjustments) necessary for a fair presentation of the results for the interim periods. Certain reclassifications have been made to the previous year's results to present comparable financial statements.

#### Subsequent Events:

Due to the net loss for the six months ended December 31, 2010, the Company did not meet two mortgage covenants. A waiver has been granted by the lender for the period. Although a waiver was granted by the lender, there is no certainty that future waivers would be granted.

#### Significant Events:

On November 25, 2009, the Company's wholly owned subsidiary, Biosearch Medical Products, Inc. ("BMPI") sold its Private Label Jejunoscopy Catheter and



## Edgar Filing: HYDROMER INC - Form 10-Q

Nasogastric Feeding Catheter business to Forefront Medical Technologies ("Forefront"), a wholly owned subsidiary of Vicplas International Limited - a company registered in the Republic of Singapore, for \$800,000 in cash, half received upon closing in November 2009 with the balance received in March 2010. This sale included inventory and equipment related to that business and also calls for the assignment of certain customer supply agreements to Forefront and a three year non-compete provision. A separate supply agreement for Hydromer(R) hydrophilic coating solution used on those products was also entered between the parties. BMPI continued manufacturing the products, at an agreed upon transfer price, until Forefront completed the transition in April 2010. Accordingly, this transaction does not meet the criteria of Discontinued Operations of Financial Accounting Standards Board Accounting Standards Codification paragraphs 205-20. These product lines sold were part of the "Medical Products" segment (see following Segment Reporting section).

### Fair Value:

Some of the Company's financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, receivables and payables. The carrying amount of the Company's note obligation approximates its fair value, as the terms of the note is consistent with terms available in the market for instruments with similar risk.

### Segment Reporting:

The Company operates two primary business segments. The Company evaluates the segments by revenues, total expenses and earnings before taxes. Corporate Overhead (primarily the salaries and benefits of senior management, support services (Accounting, Legal, Human Resources and Purchasing) and other shared services (building maintenance and warehousing) are excluded from the business segments as to not distort the contribution of each segment. These segments are the lowest levels for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.

The results for the six months ended December 31, by segment are:

	Polymer Research	Medical Products	Corporate Overhead
2010			
Revenues	\$ 1,755,262	\$ 706,755	\$
Expenses	(1,647,639)	(647,048)	(829,668)
	-----	-----	-----
Pre-tax Income (Loss)	\$ 107,623	\$ 59,707	\$ (829,668)
	=====	=====	=====
-----			
2009 (excludes the Sale of Product Lines)			
Revenues	\$ 1,884,565	\$ 1,241,120	
Expenses	(1,925,793)	(1,315,354)	\$ (795,800)
	-----	-----	-----
Pre-tax Income (Loss)	\$ (41,228)	\$ (74,234)	\$ (795,800)
	=====	=====	=====

Geographic revenues were as follows for the six months ended December 31,

	2010 ----	2009 ----
Domestic	67%	73%
Foreign	33%	27%

ITEM #2

## Edgar Filing: HYDROMER INC - Form 10-Q

### MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS

#### Results of Operations

The Company's revenues for the quarter ended December 31, 2010 were \$1,206,125, \$209,989 or 14.8% lower than the \$1,416,114 for the same period the previous year. Revenues are comprised of the sale of Products and Services and Royalty and Contract payments.

Product sales were \$560,330 for the quarter ended December 31, 2010 as compared to \$829,402 for the same period the year before, a \$269,072 (32.4%) decrease; lower primarily due to the divestiture of medical device product lines in February and November 2009. Sales from these product lines during the quarter ended December 31, 2009 totaled \$191,609. For the six month period ended December 31, 2010, product sales were \$1,210,734 as compared with \$2,011,106 or \$800,372 (39.8%) lower than the same period the year before. Sales from the divested product lines accounted for \$707,454 of the difference. Sales timing differences accounted for the remainder of the period-to-period variances.

Services revenues for the three months ended December 31, 2010 was \$401,068 or \$41,577 higher (11.6%) than the \$359,491 the corresponding period the year before. Services revenues for the six months ended December 31, 2010 was \$770,389 or \$111,106 higher (16.9%) than the \$659,283 the corresponding period the year before. Increased demand for our services, primarily on guidewires and PTCA catheters, accounted for the increase.

Royalty and Contract revenues include royalties received and the periodic recurring payments from license, stand still and other agreements for other than product and services. Included in Royalty and Contract revenues are revenues from support and supply agreements. Some of the royalties and support fees are based on the net sales of the final item (to which the Hydromer technology is applied to) and are subject to the reporting of our customers. For the quarter ended December 31, 2010, Royalty and Contract revenues were \$244,727, compared to \$227,221 the same period a year ago. For the six months ended December 31, 2010, Royalty and Contract revenues were \$480,894, \$25,598 or 5.6% higher than the previous year's period of \$455,296. We continue entering into new Royalty and Contract revenue agreements, some which begin with our customer's first commercial sale of their product. Once online, including with the commercialization of one of our hydrogel technologies, we anticipate a doubling of this revenue line within the next few years.

Discounting the lower revenues from the divested product lines, we have a modest gain in total revenues against the prior year despite the timing difference. We look to realize the timing differences sales within the next quarter or two and to further grow revenues, particularly in our T-HEXX(R) Animal Health business where a majority of our research and development during the past two years has been focused upon.

Total Expenses for the quarter ended December 31, 2010 were \$1,404,081 as compared with \$1,493,251 the year before, a 6.0% decrease. For the six months ended December 31, 2010, total expenses were \$2,914,923 as compared with \$3,475,210 the same period the year before, or 16.1% better. Reducing expenses for the three months ended December 31, 2009 was the gain from the sale of product lines of \$335,629. When excluding the gain from sale of product lines, total expenses for the three months ended December 31, 2009 would have been \$1,828,880 or with the current quarter \$424,800 (23.2%) better and \$3,810,839 for the six months period the year before or with the current year period 23.5% better (\$895,916).

## Edgar Filing: HYDROMER INC - Form 10-Q

For the quarter ended December 31, 2010, the Company's Cost of Goods Sold was \$321,983 as compared with \$627,263 the year prior, lower by \$305,281 or 48.7%. The Cost of Goods Sold attributed to the sold product lines approximated \$253,000 in the December 2009 quarter. Cost of Goods Sold for the six month period was \$748,582 or \$718,875 better (49.0%) than the prior year's \$1,467,457, which included approximately \$699,000 relating to the divested product lines.

Operating expenses were \$1,077,919 for the quarter ended December 31, 2010 as compared with \$1,221,493 the year before, lower by \$143,574 or 11.8%. For the six month period, Operating expenses were \$2,277,211 this year compared with \$2,487,853 the year before, an improvement of \$210,642 (8.5%). The prior year period included approximately \$48,000 in one-time legal fees relating to the right to market clearance work. Most of the reduction to Operating expenses related to a lower staffing level, including in part due to the divestiture of the medical device product lines, as offset by increases in marketing and sales expenses in our T-HEXX Animal Health business (added international tradeshow promotions and related travel and marketing expenditures).

Interest expense, interest income and other income are included in Other Expenses. Interest expense (on the mortgage) for the six months ended December 31, 2010 and December 31, 2009 were \$98,550 and \$100,237, respectively. Interest income for the six month periods were \$4,408 for the 2010 period as compared with \$18,589 for the 2009 period, lower due to a lower earnings base.

A net loss of \$197,956 (\$0.04 per share) is reported for the quarter ended December 31, 2010 as compared to a net loss of \$77,137 (\$0.02 per share) the year before. For the six months ended December 31, 2010, a net loss of \$452,906 (\$0.09 per share) is reported compared against a net loss of \$349,525 (\$0.07 per share) for the same period year before.

Despite having \$663,668 lower in sales this year-to-date, all attributable to the sale of the medical device product lines, expense reductions brought the pre-tax base of the two periods more on par (a difference of \$86,704 with the 2009 period gain on sale of assets reducing expenses that period or an improvement of \$248,925 when excluding the gain). However, a change to the allocation rules on taxable income for NJ State reduced the effective tax rate and Income Tax Benefit, but more so, impacted the Deferred Tax Asset and Deferred Tax Liability balances. For the quarter ended December 31, 2010, the total effect was approximately \$74,000. Had this tax change not occur, the net loss for the quarter would have been lower by approximately \$74,000 making the three and six month's results about that of the prior year. In addition, when excluding the one-time gain from the sale of assets, there would be an improvement in this year's reported results over the prior year. The Company expects to continue improvements to its results coming from increasing revenues while maintaining its expense base. The increase in revenues is anticipated to come from growth in existing business as well as new sales (new customers and new products such as the Dragonhyde(R) Hoof Bath Concentrates).

### Financial Condition

Working capital decreased \$692,111 during the six months ended December 31,

## Edgar Filing: HYDROMER INC - Form 10-Q

2010.

Net operating activities used \$489,612 during the six month period ended December 31, 2010.

The net loss, as adjusted for non-cash expenses of depreciation and amortization and deferred income taxes, used \$466,951 in cash. The net change in other operating assets and liabilities used \$22,661 in cash, with the primarily activities the collection of trade receivables offset by the reduction in accounts payable and accrued liabilities.

Investing activities provided \$284,854 and financing activities used \$24,949 during the six months ended December 31, 2010.

Investing activities for the six months ended December 31, 2010 included \$66,390 for capital expenditures and \$88,756 towards the Company's patent estate. \$440,000 in short-term investments matured and was converted into cash. Reported under Financing activities was the repayment of the principal portion of the mortgage.

We expect a turnaround in our reported results within the next few years, replacing the lost income (from the cancellation of the \$100,000 per month Supply and Support Agreement (in January 2009 which was replaced by a \$35,000 per month agreement) and from the sale of medical device product lines) with revenue growth and new revenues from new customers and new products, while controlling the expenses.

### ITEM # 3

#### Disclosure Controls and Procedures

As of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of our management, including the Chief Executive Officer and President and the Chief Financial Officer, of the effectiveness of the design and operation of the disclosure controls and procedures.

Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, our disclosure controls and procedures were effective and that there were no changes to our Company's internal control over financial reporting that have materially affected, or is reasonably likely to materially affect the Company's internal control over financial reporting during the period covered by the Company's quarterly report.

#### PART II - OTHER INFORMATION

The Company operates entirely from its sole location at 35 Industrial Parkway in Branchburg, New Jersey, an owned facility secured by a mortgage through a bank.

The existing facility will be adequate for the Company's operations for the foreseeable future.

### ITEM # 6. Exhibits

Exhibit No.	Description
31.1	Rule 13a-14(a) Certification of Chief Executive Officer

## Edgar Filing: HYDROMER INC - Form 10-Q

- and President
- 31.2 Rule 13a-14(a) Certification of Vice President of Finance and Chief Financial Officer
- 32.1 Section 1350 Certification of Chief Executive Officer and Chairman, President
- 32.2 Section 1350 Certification of Chief Financial Officer and Vice President of Finance

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on his behalf by the undersigned thereunto duly authorized.

HYDROMER, INC.  
/s/ Robert Y. Lee, VP  
-----  
Robert Y. Lee  
Principal Accounting Officer &  
Chief Financial Officer

DATE: February 22, 2011

### EXHIBIT 31.1

I, Manfred F. Dyck, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hydromer, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial

## Edgar Filing: HYDROMER INC - Form 10-Q

information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officer, Mr. Robert Y. Lee and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
  - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
  - b) designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles
  - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer, Mr. Robert Y. Lee and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
  - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officer, Mr. Robert Y. Lee and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: February 22, 2011

/s/ Manfred F. Dyck

## Edgar Filing: HYDROMER INC - Form 10-Q

-----  
Manfred F. Dyck, President and CEO

### EXHIBIT 31.2

I, Robert Y. Lee, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hydromer, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer, Mr. Manfred F. Dyck and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
  - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
  - b) designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles
  - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer, Mr. Manfred F. Dyck and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have

Edgar Filing: HYDROMER INC - Form 10-Q

identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officer, Mr. Manfred F. Dyck and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: February 22, 2011

/s/Robert Y. Lee ,VP

-----  
Robert Y. Lee, Vice President of Finance and CFO

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER  
PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Manfred F. Dyck, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Hydromer, Inc. on Form 10-Q for the six months ended December 31, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such report fairly presents in all material respects the financial condition and results of operations of Hydromer, Inc.

Date: February 22, 2011

By: /s/ Manfred F. Dyck

-----  
Manfred F. Dyck  
Chairman, President and  
Chief Executive Officer

-----  
EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER  
PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert Y. Lee, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Hydromer, Inc. on Form 10-Q for the six months ended December 31, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such report fairly presents in all material respects the financial condition and results of



Edgar Filing: HYDROMER INC - Form 10-Q

operations of Hydromer, Inc.

Date: February 22, 2011

By: /s/ Robert Y. Lee, VP

-----  
Robert Y. Lee  
Chief Financial Officer and  
Vice President of Finance